Trial Profile

An International, Multicentre, Observational, Prospective, Longitudinal Cohort Study to Assess the Impact of Integrated Upper Limb Spasticity Management Including the Use of BoNT-A- Injections on Patient-centred Goal Attainment in Real Life Practice - ULIS III

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum-Toxin-A (Primary) ; Botulinum-Toxin-A (Primary) ; Botulinum-Toxin-A (Primary)
Indications Muscle spasticity
Focus Therapeutic Use
Acronyms ULIS III
Sponsors Ipsen

18 May 2022 Results presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
15 Jan 2021 According to an Ipsen media release, data will be presented at the TOXINS 2021 conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com